# Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/severe-immune-related-adverse-events-are-common-with-sequential-pd-l-1-blockade/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Adam J. Schoenfeld,Kathryn C. Arbour,Hira Rizvi,Afsheen N. Iqbal,Shirish M. Gadgeel,Jeffrey Girshman,Mark G. Kris,Gregory J. Riely,Helena A. Yu,Matthew D. Hellmann |
| Citations | 418 |
| DOI | 10.1093/annonc/mdz077 |
| Fields | Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | http://www.annalsofoncology.org/article/S0923753419311652/pdf |
| OpenAlex ID | https://openalex.org/W2922107046 |
| PMID | 30847464 |
| Type | article |
| Year | 2019 |

## Paper authors

- [Helena A. Yu](https://scholariq.org/researchers/helena-a-yu/)
- [Mark G. Kris](https://scholariq.org/researchers/mark-g-kris/)
- [Gregory J. Riely](https://scholariq.org/researchers/gregory-j-riely/)
- [Matthew D. Hellmann](https://scholariq.org/researchers/matthew-d-hellmann/)

## Paper journal

- [Annals of Oncology](https://scholariq.org/journals/annals-of-oncology/)

## Paper primary topic

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Paper topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.